StockDuty ← Dashboard Sep 28, 2026 03:56 AM ET
SignalFDA/Bio

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ

Global Phase 3 expansion of IBI363/TAK-928 in immunotherapy-resistant NSCLC adds non-squamous patients.

What changed
Global Phase 3 expansion of IBI363/TAK-928 in immunotherapy-resistant NSCLC adds non-squamous patients.
Why it matters
Global Phase 3 expansion of IBI363/TAK-928 in immunotherapy-resistant NSCLC adds non-squamous patients. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →